IP Verse

Dana Farber Cancer Institute patent opposition analysis

Get complete Patent Opposition Report for Dana Farber Cancer Institute

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest patents of Dana Farber Cancer Institute opposed by its competitors

Explore Dana Farber Cancer Institute's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3506884Sep 25, 2024Drug Delivery Compositions And Uses Thereof1
EP3023788Feb 12, 2020Compositions Of Tumor Specific Neoantigens1
EP2423331May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2439284May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2439285May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2447375May 8, 2019Method To Determine Responsiveness Of Cancer To Epidermal Growth Factor Receptor Targeting Treatments2
EP2397155Dec 13, 2017Methods And Compositions For The Treatment Of Persistent Infections And Cancer By Inhibiting The Programmed Cell Death 1 (Pd-1)Pathway6
EP2133365May 17, 2017Compositions And Methods For The Treatment Of Infections And Tumors1

Top competitors of Dana Farber Cancer Institute